AstraZeneca's immunotherapy drug wins key lung cancer approval
Mon, Feb 19, 2018 - 5:50 AM
The approval for AstraZeneca's immunotherapy drug opens up a multibillion-dollar market for a medicine that has until now lagged behind competitors.
ASTRAZENECA'S immunotherapy drug Imfinzi has won crucial approval from US regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.
The US Food and Drug Administration said late on Friday that it...